Lamivudine‐based maintenance antiretroviral therapies in patients living with HIV ‐1 with suppressed HIV RNA : derivation of a predictive score for virological failure

Autor:	Simone Belmonti, Gianmaria Baldin, Francesca Lombardi, S Di Giambenedetto, Roberto Cauda, A. Antinori, D Speziale, Antonella Cingolani, Arturo Ciccullo, Davide Moschese, Alberto Borghetti, Arianna Emiliozzi
Rok vydání:	2019
Předmět:	Adult Male 0301 basic medicine Oncology medicine.medical_specialty Anti-HIV Agents protease inhibitors HIV Infections Settore MED/17 - MALATTIE INFETTIVE 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Predictive Value of Tests Internal medicine Drug Resistance Viral medicine Humans Pharmacology (medical) Protease inhibitor (pharmacology) 030212 general & internal medicine dolutegravir highly active antiretroviral therapy HIV therapy switch Retrospective Studies business.industry Proportional hazards model Health Policy Lamivudine Middle Aged Viral Load Resistance mutation 030112 virology Confidence interval CD4 Lymphocyte Count Infectious Diseases chemistry Dolutegravir Cohort HIV-1 RNA Viral Female business Follow-Up Studies medicine.drug Cohort study
Zdroj:	HIV Medicine. 20:624-627
ISSN:	1468-1293 1464-2662
DOI:	10.1111/hiv.12759
Popis:	OBJECTIVES Two-drug antiretroviral regimens based on lamivudine (3TC) plus either a protease inhibitor (PI) or dolutegravir (DTG) are becoming increasingly popular in switch strategies. Our goal was to derive a predictive score for virological failure (VF). METHODS We retrospectively analysed data for a cohort of 587 virologically suppressed (HIV RNA
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12c84fbdc3ab71001a9566ef0084b1d3 https://doi.org/10.1111/hiv.12759 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.